Company News - Clinical Trials Arena

Palleon Pharmaceuticals reports Phase I/II trial results of E-602 for solid tumours

gullapalli — Mon, 11 Nov 2024 07:55:11 +0000

Palleon has reported the outcomes from its Phase I/II study of E-602 with PD-1 inhibitor cemiplimab to treat patients with solid tumours.

The post Palleon Pharmaceuticals reports Phase I/II trial results of E-602 for solid tumours appeared first on Clinical Trials Arena.

OncoResponse reports data from Phase I solid tumour treatment trial

gullapalli — Fri, 08 Nov 2024 14:28:51 +0000

OncoResponse has unveiled the outcomes from the Phase I trial of OR502 for treating advanced solid tumours.

The post OncoResponse reports data from Phase I solid tumour treatment trial appeared first on Clinical Trials Arena.

Averitas completes recruitment for trial of QUTENZA to treat post-surgical pain

gullapalli — Fri, 08 Nov 2024 10:55:52 +0000

Averitas Pharma, the US subsidiary of Grünenthal, has completed patient recruitment for the Phase III AV001 study of QUTENZA to treat PSNP.

The post Averitas completes recruitment for trial of QUTENZA to treat post-surgical pain appeared first on Clinical Trials Arena.

Radella reports positive outcomes from trial of MD-18 for obesity and diabetes

gullapalli — Fri, 08 Nov 2024 09:58:56 +0000

Radella Pharmaceuticals has reported topline outcomes from a Phase Ia trial that assessed an investigational therapy for obesity and diabetes.

The post Radella reports positive outcomes from trial of MD-18 for obesity and diabetes appeared first on Clinical Trials Arena.

Minghui Pharmaceutical’s MHB039A shows promise in Phase I trial for solid tumours

gullapalli — Thu, 07 Nov 2024 15:50:26 +0000

Minghui Pharmaceutical has reported promising initial outcomes from its Phase I trial of MHB039A to treat patients with solid tumours.

The post Minghui Pharmaceutical’s MHB039A shows promise in Phase I trial for solid tumours appeared first on Clinical Trials Arena.

Customer-centricity takes spotlight during clinical transformation

Ross Law — Thu, 07 Nov 2024 12:38:39 +0000

Alcon decided to take a platform-based approach to support its clinical transformation efforts when parent company Novartis decided to spin it out as an independent organisation in 2019.

The post Customer-centricity takes spotlight during clinical transformation appeared first on Clinical Trials Arena.

Senhwa enrols first subject in Phase I/II trial of silmitasertib for solid tumours

gullapalli — Thu, 07 Nov 2024 10:59:43 +0000

Senhwa has enrolled the first subject for a Phase I/II trial of Silmitasertib in conjunction with chemotherapy to treat solid tumours.

The post Senhwa enrols first subject in Phase I/II trial of silmitasertib for solid tumours appeared first on Clinical Trials Arena.

Ionis announces design for Phase III trial of Angelman syndrome therapy

gullapalli — Thu, 07 Nov 2024 09:15:56 +0000

Ionis has announced the design for a Phase III trial of ION582, a treatment for Angelman syndrome (AS), following discussions with the FDA.

The post Ionis announces design for Phase III trial of Angelman syndrome therapy appeared first on Clinical Trials Arena.

Zymeworks doses first subject in Phase I trial of ZW191 for solid tumours

gullapalli — Wed, 06 Nov 2024 13:56:55 +0000

Zymeworks has dosed the first patient in its Phase I clinical trial of ZW191 aimed at treating advanced solid tumours.

The post Zymeworks doses first subject in Phase I trial of ZW191 for solid tumours appeared first on Clinical Trials Arena.

First patient dosed in Ankyra’s visceral tumour study of ANK-101

gullapalli — Wed, 06 Nov 2024 11:01:02 +0000

Ankyra Therapeutics has announced the dosing of the first patient with a visceral tumour in part two of its Phase I clinical trial of ANK-101.

The post First patient dosed in Ankyra’s visceral tumour study of ANK-101 appeared first on Clinical Trials Arena.